Triphase Accelerator and Catalent achieved positive interim results for Triphase Accelerator's Phase I monotherapy study of TRPH-222 in heavily pre-treated patients with relapsed and/or refractory B-cell lymphoma. The study aims to determine the maximum tolerated dose of TRPH-222, and assess safety, anti-tumor activity, and pharmacokinetics of the drug.

 
To date, results in 19 heavily pre-treated patients with non-Hodgkin’s lymphoma have been evaluated, with five confirmed to have had a complete response. Tumor reductions have been observed in patients with both indolent and aggressive disease, and durable responses have been observed in follicular, diffuse large cell, and mantle cell lymphoma patients. The trial is currently ongoing. Throughout the trial, TRPH-222 has been well-tolerated, with an overall benign safety profile.
 
"This is an important interim milestone for the program, and the data are important not only in the context of TRPH-222 but also because they signal broader opportunities for the general application of SMARTag technology to improve ADC tolerability and expand its therapeutic index," said Penelope Drake, Ph.D., Director, Research & Development at Catalent Biologics.
 
TRPH-222 was originally developed by Catalent’s subsidiary Redwood Bioscience, Inc. using its SMARTag platform, which provides optimized site-specific protein-modification and linker technologies.